- Home
- SILO vs MYNZ Comparison
SILO vs MYNZ Comparison
Compare SILO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- MYNZ
- Stock Information
- Founded
- SILO 2010
- MYNZ 2021
- Country
- SILO United States
- MYNZ Germany
- Employees
- SILO N/A
- MYNZ N/A
- Industry
- SILO Apparel
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- MYNZ Health Care
- Exchange
- SILO Nasdaq
- MYNZ Nasdaq
- Market Cap
- SILO 8.0M
- MYNZ 7.9M
- IPO Year
- SILO N/A
- MYNZ 2021
- Fundamental
- Price
- SILO $0.54
- MYNZ $1.48
- Analyst Decision
- SILO
- MYNZ Buy
- Analyst Count
- SILO 0
- MYNZ 2
- Target Price
- SILO N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- SILO 869.8K
- MYNZ 538.5K
- Earning Date
- SILO 11-12-2025
- MYNZ 12-29-2025
- Dividend Yield
- SILO N/A
- MYNZ N/A
- EPS Growth
- SILO N/A
- MYNZ N/A
- EPS
- SILO N/A
- MYNZ N/A
- Revenue
- SILO $72,102.00
- MYNZ $659,935.00
- Revenue This Year
- SILO $1.86
- MYNZ $26.06
- Revenue Next Year
- SILO N/A
- MYNZ $4.97
- P/E Ratio
- SILO N/A
- MYNZ N/A
- Revenue Growth
- SILO N/A
- MYNZ N/A
- 52 Week Low
- SILO $0.40
- MYNZ $1.28
- 52 Week High
- SILO $3.37
- MYNZ $14.39
- Technical
- Relative Strength Index (RSI)
- SILO 40.10
- MYNZ 44.06
- Support Level
- SILO $0.50
- MYNZ $1.43
- Resistance Level
- SILO $0.59
- MYNZ $1.63
- Average True Range (ATR)
- SILO 0.05
- MYNZ 0.11
- MACD
- SILO -0.00
- MYNZ -0.00
- Stochastic Oscillator
- SILO 54.31
- MYNZ 35.48
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.